PARP1 and PARylation: new keys to gut inflammation
Official title: PARP1 and PARylation as novel effectors of gut inflammation
Funded at University of Arizona · NIH-11504911 · Data updated 2026-11-12
A nearby-to-patient look at how a cellular tag called PARylation, driven by PARP1, may influence gut inflammation in inflammatory bowel disease.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Arizona NIH-funded |
| Lab location | 1 site (Tucson, United States) |
| Project start | June 1, 2023 |
| Project end | March 31, 2027 |
| Funding year | 2026 |
| Award (this year) | $27,847 |
| NIH project number | 3R01DK136240-04S1 |
| Project ID | NIH-11504911 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates are individuals with inflammatory bowel disease or at-risk populations who could donate tissue samples or participate in future translational studies.
✕Less likely to help
People without IBD or without access to related clinical samples may not benefit directly from this research.
What this research studies
This project explores how PARP1-mediated PARylation affects the gut’s response to microbiota in inflammatory bowel disease. It will study how PARP1 acts as a major writer of ADP-ribose tags in the colon and how these tags influence gene activity, barrier function, and immune regulation. Researchers plan experiments in models that reflect human colon biology to understand how changes in PARylation alter inflammation and healing after gut injury.
Why it matters
Potential benefit: If successful, the work could identify new molecular targets to reduce gut inflammation and improve mucosal healing in people with IBD.
How similar studies have gone: Prior work shows that PARP1 and PARylation are linked to mucosal inflammation and microbiota interactions, supporting potential translational relevance.
Where this research is happening
-
University of Arizona
Tucson, United States Active
Researchers
- Principal investigator: Kiela, Pawel R — University of Arizona
- Study coordinator: Kiela, Pawel R
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.